Despite numerous technological and pharmacological advances and more detailed knowledge of molecular etiologies cardiovascular diseases remain the leading cause of morbidity and mortality worldwide claiming over 17 million lives a year. indicating the need for new and more effective interventions. somatic gene therapy is one such intervention. This article summarizes current strategies being pursued for the development of clinical gene therapy for dyslipidemias that cannot effectively be treated with existing drugs. [4]. Of all the clinically applicable viral vectors (i.e. oncoretroviruses lentiviruses herpes simplex viruses adeno-associated viruses (AAVs) and adenoviruses [Ads]) the most extensive studies have been performed using Ads and AAVs. Although recombinant adenoviral vectors are extremely efficient in terms of delivering their genetic cargo to the cell nucleus transgene expression is transient due to the cellular immune responses to the transduced hepatocytes [10]. These immune responses are directed against both adenoviral proteins and the transgene product [11]. Many strategies have been devised to overcome the immune rejection associated with early-generation recombinant adenoviral vectors including immunomodulatory treatments or modification of the vector itself to reduce immune response [12 13 However there remains little justification for the use of adenoviruses for the treatment of lipoprotein disorders. Helper-dependent Ads (HD-Ads) that are deleted for all viral genes represent an important Evacetrapib advance to decrease immunogenicity and prolong transgene expression. Although HD-Ad vectors elicit reduced host-adaptive immune responses and demonstrate improved gene transfer efficiency compared with Ad vectors it is impossible to avoid innate responses after vector administration [14]. In fact it is the innate immune response to the adenoviral capsid that is associated with toxicity in humans which can be lethal. Furthermore the large-scale production of these vectors remains a practical problem [4]. Adeno-associated virus Evacetrapib vectors represent one of the most promising platforms for transducing the liver and muscle approach wherein autologous hepatocytes transduced with retroviruses Evacetrapib containing LDLR cDNA were transplanted into HoFH patients (Table 1) [41 42 Although this approach was well tolerated by patients the impact on cholesterol metabolism was modest and variable due in part to the limited amount of gene transfer achievable [41 42 More recently attention has focused on the potential of liver-directed gene therapy for HoFH. A considerable Evacetrapib number Evacetrapib of proof-of principle studies using gene transfer of the LDLR have been performed. These efforts have been facilitated by the existence of animal models for HoFH including: Table 1 Clinical trials involving gene replacement and gene inhibition for dyslipidemia conducted to date. The Watanabe heritable hyperlipidemic rabbit which is homozygous for a natural mutation in and develops hypercholesterolemia on a standard chow diet; The mouse which develops severe hypercholesterolemia when fed a high-fat diet; Second-generation models such as and [49] and WHHL rabbits [50]. This Mouse monoclonal antibody to CDK5. Cdks (cyclin-dependent kinases) are heteromeric serine/threonine kinases that controlprogression through the cell cycle in concert with their regulatory subunits, the cyclins. Althoughthere are 12 different cdk genes, only 5 have been shown to directly drive the cell cycle (Cdk1, -2, -3, -4, and -6). Following extracellular mitogenic stimuli, cyclin D gene expression isupregulated. Cdk4 forms a complex with cyclin D and phosphorylates Rb protein, leading toliberation of the transcription factor E2F. E2F induces transcription of genes including cyclins Aand E, DNA polymerase and thymidine kinase. Cdk4-cyclin E complexes form and initiate G1/Stransition. Subsequently, Cdk1-cyclin B complexes form and induce G2/M phase transition.Cdk1-cyclin B activation induces the breakdown of the nuclear envelope and the initiation ofmitosis. Cdks are constitutively expressed and are regulated by several kinases andphosphastases, including Wee1, CDK-activating kinase and Cdc25 phosphatase. In addition,cyclin expression is induced by molecular signals at specific points of the cell cycle, leading toactivation of Cdks. Tight control of Cdks is essential as misregulation can induce unscheduledproliferation, and genomic and chromosomal instability. Cdk4 has been shown to be mutated insome types of cancer, whilst a chromosomal rearrangement can lead to Cdk6 overexpression inlymphoma, leukemia and melanoma. Cdks are currently under investigation as potential targetsfor antineoplastic therapy, but as Cdks are essential for driving each cell cycle phase,therapeutic strategies that block Cdk activity are unlikely to selectively target tumor cells. has been demonstrated for AAV [49] HD-Ad [51] and lentiviral vector-mediated gene transfer [50]. Several of these vector-based approaches have demonstrated significant reductions in the development of atherosclerosis [49 51 52 with a recent AAV8 study demonstrating dramatic regression of advanced lesions as well [53]. Recently Hibbitt and colleagues have demonstrated the feasibility of somatic delivery and long-term expression of the genomic DNA LDLR transgene (>100 kb) following hydrodynamic tail vein injection [54]. The authors postulate that this vector system may provide physiological regulation of LDLR expression [55] although the efficacy of this gene transfer approach has yet to be examined in an animal model of HoFH. Antisense approaches to decrease LDL-C More recent strategies have focused on reducing total cholesterol levels by inhibiting LDL synthesis and/or secretion by the liver [56]. The first of these knockdown approaches utilized an ASO specific for apoB-100. Crooke and colleagues found that intraperitoneal injection of murine-specific apoB100 ASO resulted in significant reduction of apoB-100 (>80%) total cholesterol (25-55%) and LDL-C (40-88%) in several models of hyperlipidemia including fat-fed mice [57]. These effects were sustained for up to 6 weeks after cessation of dosing and.